Evidence map›Paper›PMID 36589700›Full record

ArticleSurgery open science2023

Is palpable DCIS more aggressive than screen-detected DCIS?

Nina Balac, Robert M Tungate, Young Ju Jeong, Heather MacDonald, Lily Tung, Naomi R Schechter, Linda Larsen, Stephen F Sener, Julie E Lang, Kirstyn E Brownson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Nina BalacKeck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Robert M TungateDepartment of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Young Ju JeongDepartment of Surgery, Catholic University of Daegu School of Medicine, Daegu 42472, Republic of Korea.
Heather MacDonaldHoag Hospital, Irvine, CA 92618, USA.
Lily TungDepartment of Trauma Surgery and Critical Care, Vancouver General Hospital, Vancouver, British Columbia V5Z 1M9, Canada.
Naomi R SchechterDepartment of Radiation Oncology, University of Southern California, Los Angeles, CA 90033, USA.
Linda LarsenDepartment of Radiology, Division of Women's Imaging, University of Southern California, Los Angeles, CA 90033, USA.
Stephen F SenerDivision of Breast, Endocrine, and Soft Tissue Surgery, Department of Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Julie E LangDivision of Breast, Endocrine, and Soft Tissue Surgery, Department of Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Kirstyn E BrownsonDivision of Breast, Endocrine, and Soft Tissue Surgery, Department of Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
University of Southern California · USCatholic University of Daegu · KRHoag Memorial Hospital Presbyterian · USLAC+USC Medical Center · USVancouver General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Palpable ductal carcinoma in-situ (pDCIS) is a subset of DCIS presenting with a clinical mass. We hypothesized pDCIS would have more aggressive clinical and pathological features, and higher rates of recurrence and upgrade to invasive disease compared to screen-detected DCIS. Materials and methods: We performed a retrospective analysis of female patients (age 28-76) with DCIS on core-needle biopsy. pDCIS patients had a physician documented palpable mass prior to initial biopsy. Descriptive statistics were performed to compare groups. Results: This study included 83 patients, 26 had pDCIS and 57 had screen-detected DCIS. Mean duration of follow-up was 49.4 months. pDCIS patients had significantly larger lesions ( Conclusions: pDCIS was associated with some aggressive pathologic and clinical features and was more frequently diagnosed by ultrasound guided core-needle biopsy than screen-detected DCIS. However, there was no significant difference in rate of recurrence or upgrade to invasive disease between groups. Key message: Although pDCIS was associated with some aggressive pathologic and clinical features, there was no significant difference in rate of recurrence or upgrade to invasive disease compared to screen-detected DCIS.

Indexed as

Breast cancerDCISDuctal carcinoma in-situPalpable DCISRecurrence ratesSentinel lymph node biopsy

Identifiers

PMID36589700
PMCPMC9798160
OpenAlexW4313419089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.